accessDx
redefining personalized therapy



COVID-19 Antibody Testing

SARS-CoV-2 Serology (COVID-19) Antibody (IgG) testing

About COVID-19 Testing

COVID-19, otherwise known as the novel coronavirus, has created a global pandemic with a high rate of transmission. Speed and certainty of detection within patient populations are key to identifying and isolating potential outbreaks and enabling employees to provide business continuity services.

The COVID-19 Antibody Test

The novel coronavirus disease 2019 (COVID-19) has created a global pandemic with a high rate of transmission. This novel disease is caused by a coronavirus called SARS-CoV-2. The Immunoglobulin M and G (IgM and IgG) antibodies to SARS-CoV-2 are proteins that the body generates as part of the adaptive immune response to the virus. IgG may remain for months after a person has recovered from an infection. IgM antibodies can be detected within a few days while IgG antibodies will be detectable from 10 days after COVID-19 symptom onset.

Detecting SARS-Cov-2 IgG antibodies helps determine if an individual was previously infected by SARS-CoV-2. Unlike molecular tests for COVID-19 (e.g., PCR), antibody testing may be better suited for public health surveillance and vaccine development than for diagnosis.[1]

The AccessDx COVID-19 Antibody test is designed to identify the presence of IgG antibodies from a patient's blood sample. This tests identifies individuals who have had previous exposure to the SARS-CoV-2 virus, even if they remained asymptomatic. It is also key in establishing the prevalence of COVID-19 in various populations. This test is available pursuant to the FDAs emergency use authorization (EUA) outlined for COVID-19 diagnostic tests.



The test utilized by AccessDx currently provides a 100% positive antibody detection rate (95% CI) for patients that are 14 days from the onset of COVID-19 symptoms, and a 91% positive antibody detection rate between 8-13 days from the onset of COVID-19 symptoms. This test requires the healthcare provider to obtain a patient's blood sample.

Seamless Integration, Unparalleled Quality

AccessDx is one of the country's leading providers of accurate, quality, and convenient COVID-19 testing. With thousands of clients from a variety of healthcare and workplace landscapes, our clients recognize our commitment to excellence. AccessDx's dedicated lab operations and client success teams are ready to help serve the needs of your organization.

Testing Statistics

- **Methodology:** Qualitative 2-step chemiluminescent microparticle immunoassay (CMIA)
- **Platform:** Abbott Laboratories
- **Specimen/Collection Process:** Requires clinical blood draw 1 SST, clot 30 min prior to spin, spin @2500-3000 RPM for 15 min
- **Laboratory Throughput:** 1,800/day, increasing weekly
- **Reimbursement:** Yes - varies
- **Kit:** Standard blood collection materials can be used and shipped to AccessDx.
- **Cold Chain:** Not required for samples up to 5 days from draw to laboratory receipt

[1]Centers for Disease Control and Prevention. Interim Guidelines for COVID-19 Antibody Testing.